We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Thermo Fisher (TMO) Q2 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
Analysts on Wall Street project that Thermo Fisher Scientific (TMO - Free Report) will announce quarterly earnings of $5.71 per share in its forthcoming report, representing an increase of 6.5% year over year. Revenues are projected to reach $11.68 billion, increasing 7.6% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Thermo Fisher metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus estimate for 'Revenues- Laboratory Products and Biopharma Services' stands at $6.46 billion. The estimate indicates a change of +7.7% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Specialty Diagnostics' reaching $1.17 billion. The estimate suggests a change of +2.8% year over year.
According to the collective judgment of analysts, 'Revenues- Life Sciences Solutions' should come in at $2.74 billion. The estimate indicates a year-over-year change of +9.6%.
The consensus among analysts is that 'Revenues- Analytical Instruments' will reach $1.81 billion. The estimate indicates a year-over-year change of +4.7%.
Shares of Thermo Fisher have experienced a change of +14.6% in the past month compared to the +0.6% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), TMO is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Exploring Analyst Estimates for Thermo Fisher (TMO) Q2 Earnings, Beyond Revenue and EPS
Analysts on Wall Street project that Thermo Fisher Scientific (TMO - Free Report) will announce quarterly earnings of $5.71 per share in its forthcoming report, representing an increase of 6.5% year over year. Revenues are projected to reach $11.68 billion, increasing 7.6% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Thermo Fisher metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus estimate for 'Revenues- Laboratory Products and Biopharma Services' stands at $6.46 billion. The estimate indicates a change of +7.7% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Specialty Diagnostics' reaching $1.17 billion. The estimate suggests a change of +2.8% year over year.
According to the collective judgment of analysts, 'Revenues- Life Sciences Solutions' should come in at $2.74 billion. The estimate indicates a year-over-year change of +9.6%.
The consensus among analysts is that 'Revenues- Analytical Instruments' will reach $1.81 billion. The estimate indicates a year-over-year change of +4.7%.
View all Key Company Metrics for Thermo Fisher here>>>Shares of Thermo Fisher have experienced a change of +14.6% in the past month compared to the +0.6% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), TMO is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .